trending Market Intelligence /marketintelligence/en/news-insights/trending/owhbbo22nvgc6bpoq4axeq2 content esgSubNav
In This List

ResApp smartphone app successfully diagnoses respiratory diseases in children

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


ResApp smartphone app successfully diagnoses respiratory diseases in children

ResApp Health Ltd said its smartphone application accurately diagnosed respiratory diseases in children during a clinical trial by recording cough sounds on a smartphone.

Researchers from The University of Queensland invented the algorithms, and the app was co-developed by the Australian healthcare technology company. ResApp said the Breathe Easy trial, which included 585 children aged 29 days to 12 years, found that the algorithms accurately diagnosed a broad range of childhood respiratory diseases when compared to clinical diagnoses.

The company said the algorithms performed very well, achieving results for asthma that were exceptional, according to a Sept. 3 press release. The app also performed favorably for pneumonia and lower respiratory tract disease.

ResApp CEO and Managing Director Tony Keating said results for pneumonia and asthma exceeded expectations. The app could be especially helpful for telehealth diagnostics, where 50% of consultations are respiratory related, he added. The company now has a dataset for regulatory submissions to commercialize its products beyond the U.S., Keating said.

Final quality assurance is ongoing in the company's U.S. Smartcough-C-2 study, and results are expected later in September, the company said.